最新消息

Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy *As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.” *This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.漢康生技（HanchorBio Inc.）於2023年3月29日在台北內湖總部成功舉辦了(SAB)科學顧問委員會會議。